No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Brain health software group Cambridge Cognition said on Tuesay that full-year revenues were expected to be no less than £10.0m, while adjusted underlying earnings was seen at close to breakeven.
Cambridge Cognition noted that following its operational reorganisation at the end of Q3, the highest levels of both sales orders and book-to-bill ratio in FY24 was recorded in October.
Encouragingly, sales orders secured during H2 included an increasing number of multi-product contracts, particularly including eCOA, AQUA and voice recognition, which were brought into the portfolio through the Winterlight and eClinicalHealth acquisitions. In addition, Cambridge Cognition there was an increasing number of repeat orders from top-tier pharmaceutical customers.
However, the AIM-listed group stated that with most of its new sales orders secured in Q4, much of the revenue will be recognised in FY25 or later.
Cambridge Cognition also highlighted that it now had greater revenue visibility into FY25, with a strengthened order book of £13.5m and a growing sales pipeline of over £34.0m.
As of 1335 GMT, Cambridge Cognition shares were up 6.14% at 31.31p.
Reporting by Iain Gilbert at Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.
